These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 18395375)

  • 1. [Efavirenz versus indinavir among HIV-1 naive patients in Abidjan (Ivory Coast)].
    Tanon AK; Eholié SP; Polneau S; Kra O; Ello F; Ehui E; Aoussi E; Djadji A; Kakou A; Bissagnéné E; Kadio A
    Med Mal Infect; 2008 May; 38(5):264-9. PubMed ID: 18395375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of indinavir + ritonavir 600 + 100 mg vs. 400 + 100 mg BID combinations in HIV1-infected patients guided by therapeutic drug monitoring.
    Wasmuth JC; Rodermann E; Voigt E; Vogel M; Lauenroth-Mai E; Jessen A; Burger D; Rockstroh JK
    Eur J Med Res; 2007 Jul; 12(7):289-94. PubMed ID: 17933700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of indinavir-associated nephrological complications in HIV-infected adults (predominantly women) with high indinavir plasma concentration in Abidjan, Côte d'Ivoire.
    Danel C; Moh R; Peytavin G; Anzian A; Minga A; Gomis OB; Seri B; Nzunettu G; Gabillard D; Salamon R; Bissagnene E; Anglaret X
    AIDS Res Hum Retroviruses; 2007 Jan; 23(1):62-6. PubMed ID: 17263634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: immunovirological outcome and side effects.
    Bongiovanni M; Bini T; Chiesa E; Cicconi P; Adorni F; Monforte d'Arminio A
    Antiviral Res; 2004 Apr; 62(1):53-6. PubMed ID: 15026202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800/100 mg and 400/100 mg twice daily.
    Konopnicki D; De Wit S; Poll B; Crommentuyn K; Huitema A; Clumeck N
    HIV Med; 2005 Jan; 6(1):1-6. PubMed ID: 15670245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on study 006--EFV + AZT + 3TC versus the current 'standard of care' IDV + AZT + 3TC.
    Staszewski S
    Int J Clin Pract Suppl; 1999 Jun; 103():10-5. PubMed ID: 10622037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients.
    Duval X; Peytavin G; Albert I; Bénoliel S; Ecobichon JL; Brun-Vézinet F; Mentré F; Leport C; Vildé JL
    HIV Med; 2004 Jul; 5(4):307-13. PubMed ID: 15236622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load.
    Arnaiz JA; Mallolas J; Podzamczer D; Gerstoft J; Lundgren JD; Cahn P; Fätkenheuer G; D'Arminio-Monforte A; Casiró A; Reiss P; Burger DM; Stek M; Gatell JM;
    AIDS; 2003 Apr; 17(6):831-40. PubMed ID: 12660530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virologic and immunologic responses to antiretroviral therapy among HIV-1 and HIV-2 dually infected patients: case reports from Abidjan, Côte d'Ivoire.
    Borget MY; Diallo K; Adje-Toure C; Chorba T; Nkengasong JN
    J Clin Virol; 2009 May; 45(1):72-5. PubMed ID: 19375979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morbidity in HIV-1-Infected children treated or not treated with highly active antiretroviral therapy (HAART), Abidjan, Cote d'Ivoire, 2000-04.
    Walenda C; Kouakoussui A; Rouet F; Wemin L; Anaky MF; Msellati P
    J Trop Pediatr; 2009 Jun; 55(3):170-6. PubMed ID: 19066169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of escin on indinavir crystallization time in the urine of patients with HIV-I infection: a multicenter, randomized, open-label, controlled, four-period crossover trial.
    Grases F; García-González R; Redondo E; Costa-Bauzá A; Simonet BM; Sartini RP; Bassa A; Gallegos C; Payeras A; Saro D; Martinez AI; Cifuentes C; Homar F; Murillo JA; Fernández C; Riera M; Conte A
    Clin Ther; 2004 Dec; 26(12):2045-55. PubMed ID: 15823768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience.
    Demeter LM; DeGruttola V; Lustgarten S; Bettendorf D; Fischl M; Eshleman S; Spreen W; Nguyen BY; Koval CE; Eron JJ; Hammer S; Squires K
    HIV Clin Trials; 2008; 9(1):11-25. PubMed ID: 18215978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity.
    Wasmuth JC; Lambertz I; Voigt E; Vogel M; Hoffmann C; Burger D; Rockstroh JK
    Eur J Clin Pharmacol; 2007 Oct; 63(10):901-8. PubMed ID: 17690876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paronychia in association with indinavir treatment.
    Colson AE; Sax PE; Keller MJ; Turk BK; Pettus PT; Platt R; Choo PW
    Clin Infect Dis; 2001 Jan; 32(1):140-3. PubMed ID: 11118393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular indinavir pharmacokinetics in HIV-infected patients: comparison with plasma pharmacokinetics.
    Hennessy M; Clarke S; Spiers JP; Mulcahy F; Kelleher D; Meadon E; Maher B; Bergin C; Khoo S; Tjia J; Hoggard P; Back D; Barry M
    Antivir Ther; 2003 Jun; 8(3):191-8. PubMed ID: 12924535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic study of the variability of indinavir drug levels when boosted with ritonavir in HIV-infected children.
    Curras V; Hocht C; Mangano A; Niselman V; Mariño Hernández E; Cáceres Guido P; Mecikovsky D; Bellusci C; Bologna R; Sen L; Rubio MC; Bramuglia GF
    Pharmacology; 2009; 83(1):59-66. PubMed ID: 19052483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Nutrition problems experienced by adults infected with the human immunodeficiency virus in Abidjan (Ivory Coast)].
    Castetbon K; Attia A; Anglaret X; N'Dri-Yoman T; Sylla-Koko F; Malvy D; Cotrimo-Ci FD
    Sante; 2000; 10(1):11-7. PubMed ID: 10827357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review.
    Bierman WF; van Agtmael MA; Nijhuis M; Danner SA; Boucher CA
    AIDS; 2009 Jan; 23(3):279-91. PubMed ID: 19114854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid changes in patients initiating efavirenz- and indinavir-based antiretroviral regimens.
    Tashima KT; Bausserman L; Alt EN; Aznar E; Flanigan TP
    HIV Clin Trials; 2003; 4(1):29-36. PubMed ID: 12577194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.